WallStSmart

Becton Dickinson and Company (BDX)vsVuzix Corp Cmn Stk (VUZI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 348975% more annual revenue ($21.92B vs $6.28M). BDX leads profitability with a 8.0% profit margin vs 0.0%. BDX earns a higher WallStSmart Score of 63/100 (C+).

BDX

Buy

63

out of 100

Grade: C+

Growth: 5.3Profit: 5.5Value: 6.7Quality: 5.5
Piotroski: 6/9Altman Z: 1.49

VUZI

Avoid

26

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: -4.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+25.3%)

Margin of Safety

+25.3%

Fair Value

$241.89

Current Price

$149.43

$92.46 discount

UndervaluedFair: $241.89Overvalued
VUZIUndervalued (+43.1%)

Margin of Safety

+43.1%

Fair Value

$4.34

Current Price

$3.11

$1.23 discount

UndervaluedFair: $4.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX2 strengths · Avg: 8.0/10
Price/BookValuation
1.7x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

VUZI2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
76.3%10/10

Revenue surging 76.3% year-over-year

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Areas to Watch

BDX4 concerns · Avg: 3.3/10
P/E RatioValuation
26.8x4/10

Moderate valuation

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

VUZI4 concerns · Avg: 3.5/10
Price/BookValuation
10.4x4/10

Trading at 10.4x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$239.50M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Price/Book, EPS Growth. PEG of 1.12 suggests the stock is reasonably priced for its growth.

Bull Case : VUZI

The strongest argument for VUZI centers on Revenue Growth, Debt/Equity. Revenue growth of 76.3% demonstrates continued momentum.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : VUZI

The primary concerns for VUZI are Price/Book, EPS Growth, Market Cap.

Key Dynamics to Monitor

BDX profiles as a value stock while VUZI is a hypergrowth play — different risk/reward profiles.

VUZI carries more volatility with a beta of 1.52 — expect wider price swings.

VUZI is growing revenue faster at 76.3% — sustainability is the question.

BDX generates stronger free cash flow (546M), providing more financial flexibility.

Bottom Line

BDX scores higher overall (63/100 vs 26/100). VUZI offers better value entry with a 43.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Vuzix Corp Cmn Stk

TECHNOLOGY · CONSUMER ELECTRONICS · USA

Vuzix Corporation designs, manufactures, markets and sells augmented reality (AR) computing and display devices for consumer and business markets in North America, Asia-Pacific, Europe, and internationally. The company is headquartered in West Henrietta, New York.

Want to dig deeper into these stocks?